Drug Profile

ABarginase - ABRAM Therapeutics

Latest Information Update: 10 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hong Kong Polytechnic University; The Chinese University of Hong Kong
Developer ABRAM Therapeutics
Class Enzymes; Obesity therapies; Recombinant fusion proteins
Mechanism of Action Arginase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Metabolic disorders; Obesity

Most Recent Events

10 Jun 2025 ABRAM Therapeutics plans a first in human clinical trial in Obesity and Metabolic disorders by end of 2026
12 May 2025 ABRAM Therapeutics has patents related to composition and application of ABarginase, before May 2025
12 May 2025 ABRAM Therapeutics has patents pending ted related to composition and application of ABarginase, before May 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com